Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery of Influenza Polymerase PA–PB1 Interaction Inhibitors Using an In Vitro Split-Luciferase Complementation-Based Assay
Jiantao Zhang, Yanmei Hu, Nan Wu, et al.
ACS Chemical Biology (2019) Vol. 15, Iss. 1, pp. 74-82
Open Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

Thein vitroantiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor
Yanmei Hu, Xiangzhi Meng, Fushun Zhang, et al.
Emerging Microbes & Infections (2021) Vol. 10, Iss. 1, pp. 317-330
Open Access | Times Cited: 165
Rational Design of Peptide-Based Inhibitors Disrupting Protein-Protein Interactions
Xuefei Wang, Duan Ni, Yaqin Liu, et al.
Frontiers in Chemistry (2021) Vol. 9
Open Access | Times Cited: 109
An Overview of Antivirals against Monkeypox Virus and Other Orthopoxviruses
Jun Wang, Md Shahed-AI-Mahmud, Angelo Chen, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 7, pp. 4468-4490
Closed Access | Times Cited: 46
Brilacidin, a COVID‐19 drug candidate, demonstrates broad‐spectrum antiviral activity against human coronaviruses OC43, 229E, and NL63 through targeting both the virus and the host cell
Yanmei Hu, Hyunil Jo, William F. DeGrado, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 5, pp. 2188-2200
Open Access | Times Cited: 38
Antiviral strategies against influenza virus: an update on approved and innovative therapeutic approaches
Anna Bonomini, Beatrice Mercorelli, Arianna Loregian
Cellular and Molecular Life Sciences (2025) Vol. 82, Iss. 1
Open Access
Inhibition of Influenza Virus Polymerase by Interfering with Its Protein–Protein Interactions
Serena Massari, Jenny Desantis, Maria Giulia Nizi, et al.
ACS Infectious Diseases (2020) Vol. 7, Iss. 6, pp. 1332-1350
Open Access | Times Cited: 29
Optimization of potent, broad-spectrum, and specific anti-influenza compounds targeting RNA polymerase PA-PB1 heterodimerization
Anna Bonomini, Tommaso Felicetti, Martina Pacetti, et al.
European Journal of Medicinal Chemistry (2024) Vol. 277, pp. 116737-116737
Closed Access | Times Cited: 3
Protein-fragment complementation assays for large-scale analysis of protein–protein interactions
Ewa Błaszczak, Natalia Lazarewicz, Aswani Sudevan, et al.
Biochemical Society Transactions (2021) Vol. 49, Iss. 3, pp. 1337-1348
Open Access | Times Cited: 20
Luciferase-Based Biosensors in the Era of the COVID-19 Pandemic
Taha Azad, Helena J. Janse van Rensburg, Jessica Morgan, et al.
ACS Nanoscience Au (2021) Vol. 1, Iss. 1, pp. 15-37
Open Access | Times Cited: 19
Contemporary medicinal chemistry strategies for the discovery and optimization of influenza inhibitors targeting vRNP constituent proteins
Lingxin Hou, Ying Zhang, Han Ju, et al.
Acta Pharmaceutica Sinica B (2021) Vol. 12, Iss. 4, pp. 1805-1824
Open Access | Times Cited: 19
Docking-based workflow and ADME prediction of some compounds in Curcuma longa and Andrographis paniculata as polymerase PA-PB1 inhibitors of influenza A/H5N1 virus
Sitti Nur Aidah Lya CITRA, Arfan Arfan, Alrum Armid, et al.
Journal of Research in Pharmacy (2023) Vol. 27(1), Iss. 27(1), pp. 221-231
Open Access | Times Cited: 7
Searching for effective antiviral small molecules against influenza A virus: A patent review
Tiziana Ginex, F. Javier Luque
Expert Opinion on Therapeutic Patents (2020) Vol. 31, Iss. 1, pp. 53-66
Open Access | Times Cited: 18
Boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against coronaviruses in cell culture
Yanmei Hu, Chunlong Ma, Tommy Szeto, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 15
Cytopathic Effect Assay and Plaque Assay to Evaluate in vitro Activity of Antiviral Compounds Against Human Coronaviruses 229E, OC43, and NL63
Yanmei Hu, Chunlong Ma, Jun Wang
BIO-PROTOCOL (2022) Vol. 12, Iss. 3
Open Access | Times Cited: 9
Approaches for discovery of small-molecular antivirals targeting to influenza A virus PB2 subunit
Wenteng Chen, Jiaan Shao, Zhimin Ying, et al.
Drug Discovery Today (2022) Vol. 27, Iss. 6, pp. 1545-1553
Open Access | Times Cited: 9
Current advances in the use of bioluminescence assays for drug discovery: an update of the last ten years
Maria Maddalena Calabretta, Elisa Michelini
Expert Opinion on Drug Discovery (2023) Vol. 19, Iss. 1, pp. 85-95
Closed Access | Times Cited: 5
Lead Optimization of Influenza Virus RNA Polymerase Inhibitors Targeting PA–PB1 Interaction
Satoshi Mizuta, Hiroki Otaki, Takeshi Ishikawa, et al.
Journal of Medicinal Chemistry (2021) Vol. 65, Iss. 1, pp. 369-385
Closed Access | Times Cited: 9
Anti-Influenza Drug Discovery and Development: Targeting the Virus and Its Host by All Possible Means
Olivier Terrier, Anny Slama‐Schwok
Advances in experimental medicine and biology (2021), pp. 195-218
Closed Access | Times Cited: 8
Thermodynamic and structural characterization of an optimized peptide-based inhibitor of the influenza polymerase PA-PB1 subunit interaction
Kateřina Radilová, Václav Zima, Michal Kráľ, et al.
Antiviral Research (2022) Vol. 208, pp. 105449-105449
Closed Access | Times Cited: 4
structural characterization of the interaction between the C-terminal domain of the influenza polymerase PA subunit and an optimized small peptide inhibitor
Jakub Hejdánek, Kateřina Radilová, Petr Pachl, et al.
Antiviral Research (2020) Vol. 185, pp. 104971-104971
Open Access | Times Cited: 5
Semisynthetic Cardenolides Acting as Antiviral Inhibitors of Influenza A Virus Replication by Preventing Polymerase Complex Formation
Laurita Boff, André Schreiber, Aline da Rocha Matos, et al.
Molecules (2020) Vol. 25, Iss. 20, pp. 4853-4853
Open Access | Times Cited: 4
Experimental and Analytical Framework for “Mix-and-Read” Assays Based on Split Luciferase
Nikki McArthur, Carlos Cruz‐Teran, Apoorva Thatavarty, et al.
ACS Omega (2022) Vol. 7, Iss. 28, pp. 24551-24560
Open Access | Times Cited: 3
Acquisition of Avian-Origin PB1 Facilitates Viral RNA Synthesis by the 2009 Pandemic H1N1 Virus Polymerase
Fangzheng Wang, Guanqun Liu, Yao Lu, et al.
Viruses (2020) Vol. 12, Iss. 3, pp. 266-266
Open Access | Times Cited: 2
Brilacidin, a COVID-19 Drug Candidate, demonstrates broad-spectrum antiviral activity against human coronaviruses OC43, 229E and NL63 through targeting both the virus and the host cell
Yanmei Hu, Hyunil Jo, William F. DeGrado, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 1
Development and characterization of an inducible assay system to measure Zika virus capsid interactions
Jieshi Yu, Huang Chen, Zhao Wang, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 11, pp. 5392-5400
Open Access
Page 1 - Next Page

Scroll to top